David J. Mayman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
David J. Mayman has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Peter Keyes Sculco
Complex Joint Reconstruction Center, Adult Reconstruction and Joint Replacement Service, Hospital for Special Surgery New York New York USA
5 shared publications - Jonathan M. Vigdorchik
Hospital for Special Surgery, New York, NY
3 shared publications - Seong Jun Jang
Department of Orthopedic Surgery, Hospital for Special Surgery, New York, NY, USA
3 shared publications - Christopher G. Anderson
Department of Orthopedic Surgery, Hospital for Special Surgery, New York, NY, USA
2 shared publications - Edwin P. Su
Hospital for Special Surgery 535 E 70(th) st, New York, NY 10021
2 shared publications - Geoffrey H. Westrich
Hospital for Special Surgery New York City New York USA
2 shared publications
Latest Publications
- Open Access
Patient-Derived Synovium-on-a-Chip Recapitulates Disease and Treatment Response and Permits Study of Resistance in Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic inflammatory disease with substantial interpatient heterogeneity in synovial pathology and therapeutic response. Reliable methods to predict drug efficacy for a given patients remain a critical unmet need. We developed a vascularized, immunocompetent synovium-on-a-chip platform that integrates patient-derived fibroblast-like synoviocytes (FLS) with matched peripheral blood leukocytes to provide a physiological human model of RA. The platform reconstructed the lining–sublining synovial architecture, recapitulated key features of RA inflammation, and exhibited transcriptional profiles resembling those of patient synovial tissue. Across patients spanning low, mixed, and high inflammatory endotypes, stromal– vascular organization was associated with distinct immune cell positioning and activation patterns, and on-chip immune phenotypes correlated with histological joint inflammation scores. We then tested infliximab, tocilizumab, and tofacitinib in parallel and integrated cytokine secretion, extracellular matrix remodeling, immune cell survival and immune cell recruitment into a composite treatment response score. On-chip scores for clinically matched treatments correlated with clinical improvement measured by ΔDAS28–ESR (Pearson r = 0.844). To investigate the cellular basis of heterogeneous drug responses, single-cell RNA sequencing identified SFRP1⁺ remodeling FLS that persisted under treatment and exhibited high inflammatory programs in poorly responding chips. Cell–cell communication analysis linked reduced FN1–CD44 signaling toward SFRP1⁺ remodeling FLS to higher NF-κB activity and drug resistance. We tested the functional relevance of this finding in chips derived from an independent TNFi-nonresponsive patient, where fibronectin supplementation reduced IL-6 secretion and restored the composite treatment response. Together, these findings support patient-derived synovium-on-a-chip as a platform for individualized drug evaluation and identify ECM-mediated niche signaling as a potential therapeutic target for overcoming drug resistance in RA. One Sentence Summary: A patient-derived immunocompetent synovium-on-a-chip recapitulates rheumatoid arthritis joint biology in vitro, accurately tests patient therapeutic response and reveals a SFRP1⁺ FLS-mediated resistance mechanism in rheumatoid arthritis.
Open AccessPatient-Derived Synovium-on-a-Chip Recapitulates Disease and Treatment Response and Permits Study of Resistance in Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic inflammatory disease with substantial interpatient heterogeneity in synovial pathology and therapeutic response. Reliable methods to predict drug efficacy for a given patients remain a critical unmet need. We developed a vascularized, immunocompetent synovium-on-a-chip platform that integrates patient-derived fibroblast-like synoviocytes (FLS) with matched peripheral blood leukocytes to provide a physiological human model of RA. The platform reconstructed the lining–sublining synovial architecture, recapitulated key features of RA inflammation, and exhibited transcriptional profiles resembling those of patient synovial tissue. Across patients spanning low, mixed, and high inflammatory endotypes, stromal– vascular organization was associated with distinct immune cell positioning and activation patterns, and on-chip immune phenotypes correlated with histological joint inflammation scores. We then tested infliximab, tocilizumab, and tofacitinib in parallel and integrated cytokine secretion, extracellular matrix remodeling, immune cell survival and immune cell recruitment into a composite treatment response score. On-chip scores for clinically matched treatments correlated with clinical improvement measured by ΔDAS28–ESR (Pearson r = 0.844). To investigate the cellular basis of heterogeneous drug responses, single-cell RNA sequencing identified SFRP1⁺ remodeling FLS that persisted under treatment and exhibited high inflammatory programs in poorly responding chips. Cell–cell communication analysis linked reduced FN1–CD44 signaling toward SFRP1⁺ remodeling FLS to higher NF-κB activity and drug resistance. We tested the functional relevance of this finding in chips derived from an independent TNFi-nonresponsive patient, where fibronectin supplementation reduced IL-6 secretion and restored the composite treatment response. Together, these findings support patient-derived synovium-on-a-chip as a platform for individualized drug evaluation and identify ECM-mediated niche signaling as a potential therapeutic target for overcoming drug resistance in RA. One Sentence Summary: A patient-derived immunocompetent synovium-on-a-chip recapitulates rheumatoid arthritis joint biology in vitro, accurately tests patient therapeutic response and reveals a SFRP1⁺ FLS-mediated resistance mechanism in rheumatoid arthritis.
- Open Access
- 1 September 2026
- Published by The Korean Hip Society in Hip & Pelvis
- Vol. 38 (3) , 234-241
Automated Femoral, Acetabular, and Global Offset Measurements on Pelvis Radiograph Using Deep Learning
Jack C. Casey, BS, Seong J. Jang, MD, Billy I. Kim, MD, Kyle N. Kunze, MD, Chris Anderson, MD, David J. Mayman, MD, Seth A. Jerabek, MD, Jonathan M. Vigdorchik, MD, Peter K. Sculco, MD. Hip Pelvis 2026;38:234-41. https://doi.org/10.5371/hp.2026.38.3.234
- 1 September 2026
- Published by The Korean Hip Society in Hip & Pelvis
- Vol. 38 (3) , 234-241
Open AccessAutomated Femoral, Acetabular, and Global Offset Measurements on Pelvis Radiograph Using Deep Learning
Jack C. Casey, BS, Seong J. Jang, MD, Billy I. Kim, MD, Kyle N. Kunze, MD, Chris Anderson, MD, David J. Mayman, MD, Seth A. Jerabek, MD, Jonathan M. Vigdorchik, MD, Peter K. Sculco, MD. Hip Pelvis 2026;38:234-41. https://doi.org/10.5371/hp.2026.38.3.234
- 29 June 2023
- Published by Wiley in Knee Surgery, Sports Traumatology, Arthroscopy
- Vol. 31 (11) , 4735-4740
High degree of alignment precision associated with total knee arthroplasty performed using a surgical robot or handheld navigation
Purpose: The purpose of this study was to compare the precision of bony resections during total knee arthroplasty (TKA) performed using different computer‐assisted technologies.Methods: Patients who underwent a primary TKA using an imageless accelerometer‐based handheld navigation system (KneeAlign2®, OrthAlign Inc.) or computed tomography‐based large‐console surgical robot (Mako®, Stryker Corp.) from 2017 to 2020 were retrospectively reviewed. Templated alignment targets and demographic data were collected. Coronal plane alignment of the femoral and tibial components and tibial slope were measured on postoperative radiographs. Patients with excessive flexion or rotation preventing accurate measurement were excluded.Results: A total of 240 patients who underwent TKA using either a handheld (n = 120) or robotic (n = 120) system were included. There were no statistically significant differences in age, sex, and BMI between groups. A small but statistically significant difference in the precision of the distal femoral resection was observed between the handheld and robotic cohorts (1.5° vs. 1.1° difference between templated and measured alignments, p = 0.024), though this is likely clinically insignificant. There were no significant differences in the precision of the tibial resection between the handheld and robotic groups (coronal plane 0.9° vs. 1.0°, n.s.; sagittal plane 1.2° vs. 1.1°, n.s.). There were no significant differences in the rate of overall precision between cohorts (n.s.).Conclusions: A high degree of component alignment precision was observed for both imageless handheld navigation and CT‐based robotic cohorts. Surgeons considering options for computer‐assisted TKA should take other important factors, including surgical principles, templating software, ligament balancing, intraoperative adjustability, equipment logistics, and cost, into account.Level of evidence: III.
- 29 June 2023
- Published by Wiley in Knee Surgery, Sports Traumatology, Arthroscopy
- Vol. 31 (11) , 4735-4740
High degree of alignment precision associated with total knee arthroplasty performed using a surgical robot or handheld navigation
Purpose: The purpose of this study was to compare the precision of bony resections during total knee arthroplasty (TKA) performed using different computer‐assisted technologies.Methods: Patients who underwent a primary TKA using an imageless accelerometer‐based handheld navigation system (KneeAlign2®, OrthAlign Inc.) or computed tomography‐based large‐console surgical robot (Mako®, Stryker Corp.) from 2017 to 2020 were retrospectively reviewed. Templated alignment targets and demographic data were collected. Coronal plane alignment of the femoral and tibial components and tibial slope were measured on postoperative radiographs. Patients with excessive flexion or rotation preventing accurate measurement were excluded.Results: A total of 240 patients who underwent TKA using either a handheld (n = 120) or robotic (n = 120) system were included. There were no statistically significant differences in age, sex, and BMI between groups. A small but statistically significant difference in the precision of the distal femoral resection was observed between the handheld and robotic cohorts (1.5° vs. 1.1° difference between templated and measured alignments, p = 0.024), though this is likely clinically insignificant. There were no significant differences in the precision of the tibial resection between the handheld and robotic groups (coronal plane 0.9° vs. 1.0°, n.s.; sagittal plane 1.2° vs. 1.1°, n.s.). There were no significant differences in the rate of overall precision between cohorts (n.s.).Conclusions: A high degree of component alignment precision was observed for both imageless handheld navigation and CT‐based robotic cohorts. Surgeons considering options for computer‐assisted TKA should take other important factors, including surgical principles, templating software, ligament balancing, intraoperative adjustability, equipment logistics, and cost, into account.Level of evidence: III.
- 9 March 2023
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 38 (10) , 2017-2023.e3
Leg-Length Discrepancy Variability on Standard Anteroposterior Pelvis Radiographs: An Analysis Using Deep Learning Measurements
- 9 March 2023
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 38 (10) , 2017-2023.e3
Leg-Length Discrepancy Variability on Standard Anteroposterior Pelvis Radiographs: An Analysis Using Deep Learning Measurements
- Open Access
- 1 June 2022
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Open
- Vol. 3 (6) , 475-484
Abnormal spinopelvic mobility as a risk factor for acetabular placement error in total hip arthroplasty using optical computer-assisted surgical navigation system
Aims: Navigation devices are designed to improve a surgeon’s accuracy in positioning the acetabular and femoral components in total hip arthroplasty (THA). The purpose of this study was to both evaluate the accuracy of an optical computer-assisted surgery (CAS) navigation system and determine whether preoperative spinopelvic mobility (categorized as hypermobile, normal, or stiff) increased the risk of acetabular component placement error. Methods: A total of 356 patients undergoing primary THA were prospectively enrolled from November 2016 to March 2018. Clinically relevant error using the CAS system was defined as a difference of > 5° between CAS and 3D radiological reconstruction measurements for acetabular component inclination and anteversion. Univariate and multiple logistic regression analyses were conducted to determine whether hypermobile ([ ]sacral slope(SS)stand-sit > 30°), or stiff ([ ]SSstand-sit < 10°) spinopelvic mobility contributed to increased error rates. Results: The paired absolute difference between CAS and postoperative imaging measurements was 2.3° (standard deviation (SD) 2.6°) for inclination and 3.1° (SD 4.2°) for anteversion. Using a target zone of 40° (± 10°) (inclination) and 20° (± 10°) (anteversion), postoperative standing radiographs measured 96% of acetabular components within the target zone for both inclination and anteversion. Multiple logistic regression analysis controlling for BMI and sex revealed that hypermobile spinopelvic mobility significantly increased error rates for anteversion (odds ratio (OR) 2.48, p = 0.009) and inclination (OR 2.44, p = 0.016), whereas stiff spinopelvic mobility increased error rates for anteversion (OR 1.97, p = 0.028). There were no dislocations at a minimum three-year follow-up. Conclusion: Despite high reliability in acetabular positioning for inclination in a large patient cohort using an optical CAS system, hypermobile and stiff spinopelvic mobility significantly increased the risk of clinically relevant errors. In patients with abnormal spinopelvic mobility, CAS systems should be adjusted for use to avoid acetabular component misalignment and subsequent risk for long-term dislocation. Cite this article: Bone Jt Open 2022;3(6):475–484.
- 1 June 2022
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Open
- Vol. 3 (6) , 475-484
Open AccessAbnormal spinopelvic mobility as a risk factor for acetabular placement error in total hip arthroplasty using optical computer-assisted surgical navigation system
Aims: Navigation devices are designed to improve a surgeon’s accuracy in positioning the acetabular and femoral components in total hip arthroplasty (THA). The purpose of this study was to both evaluate the accuracy of an optical computer-assisted surgery (CAS) navigation system and determine whether preoperative spinopelvic mobility (categorized as hypermobile, normal, or stiff) increased the risk of acetabular component placement error. Methods: A total of 356 patients undergoing primary THA were prospectively enrolled from November 2016 to March 2018. Clinically relevant error using the CAS system was defined as a difference of > 5° between CAS and 3D radiological reconstruction measurements for acetabular component inclination and anteversion. Univariate and multiple logistic regression analyses were conducted to determine whether hypermobile ([ ]sacral slope(SS)stand-sit > 30°), or stiff ([ ]SSstand-sit < 10°) spinopelvic mobility contributed to increased error rates. Results: The paired absolute difference between CAS and postoperative imaging measurements was 2.3° (standard deviation (SD) 2.6°) for inclination and 3.1° (SD 4.2°) for anteversion. Using a target zone of 40° (± 10°) (inclination) and 20° (± 10°) (anteversion), postoperative standing radiographs measured 96% of acetabular components within the target zone for both inclination and anteversion. Multiple logistic regression analysis controlling for BMI and sex revealed that hypermobile spinopelvic mobility significantly increased error rates for anteversion (odds ratio (OR) 2.48, p = 0.009) and inclination (OR 2.44, p = 0.016), whereas stiff spinopelvic mobility increased error rates for anteversion (OR 1.97, p = 0.028). There were no dislocations at a minimum three-year follow-up. Conclusion: Despite high reliability in acetabular positioning for inclination in a large patient cohort using an optical CAS system, hypermobile and stiff spinopelvic mobility significantly increased the risk of clinically relevant errors. In patients with abnormal spinopelvic mobility, CAS systems should be adjusted for use to avoid acetabular component misalignment and subsequent risk for long-term dislocation. Cite this article: Bone Jt Open 2022;3(6):475–484.
- 20 September 2019
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 101 (23) , 2120-2128
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement
Background: Tranexamic acid (TXA) is an antifibrinolytic drug. Topical administration of TXA during total knee arthroplasty (TKA) is favored for certain patients because of concerns about thrombotic complications, despite a lack of supporting literature. We compared local and systemic levels of thrombogenic markers, interleukin (IL)-6, and TXA between patients who received intravenous (IV) TXA and those who received topical TXA. Methods: Seventy-six patients scheduled for TKA were enrolled in this randomized double-blinded study. The IV group received 1.0 g of IV TXA before tourniquet inflation and again 3 hours later; a topical placebo was administered 5 minutes before final tourniquet release. The topical group received an IV placebo before tourniquet inflation and again 3 hours later; 3.0 g of TXA was administered topically 5 minutes before final tourniquet release. Peripheral and wound blood samples were collected to measure levels of plasmin-anti-plasmin (PAP, a measure of fibrinolysis), prothrombin fragment 1.2 (PF1.2, a marker of thrombin generation), IL-6, and TXA. Results: At 1 hour after tourniquet release, systemic PAP levels were comparable between the IV group (after a single dose of IV TXA) and the topical group. At 4 hours after tourniquet release, the IV group had lower systemic PAP levels than the topical group (mean and standard deviation, 1,117.8 ± 478.9 µg/L versus 1,280.7 ± 646.5 µg/L; p = 0.049), indicative of higher antifibrinolytic activity after the second dose. There was no difference in PF1.2 levels between groups, indicating that there was no increase in thrombin generation. The IV group had higher TXA levels at all time points (p < 0.001). Four hours after tourniquet release, wound blood IL-6 and TXA levels were higher than systemic levels in both groups (p < 0.001). Therapeutic systemic TXA levels (mean, 7.2 ± 7.4 mg/L) were noted in the topical group. Calculated blood loss and the length of the hospital stay were lower in the IV group (p = 0.026 and p = 0.025). Conclusions: Given that therapeutic levels were reached with topical TXA and the lack of a major difference in the mechanism of action, coagulation, and fibrinolytic profile between topical TXA and a single dose of IV TXA, it may be a simpler protocol for institutions to adopt the use of a single dose of IV TXA when safety is a concern. Level of Evidence: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.
- 20 September 2019
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 101 (23) , 2120-2128
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement
Background: Tranexamic acid (TXA) is an antifibrinolytic drug. Topical administration of TXA during total knee arthroplasty (TKA) is favored for certain patients because of concerns about thrombotic complications, despite a lack of supporting literature. We compared local and systemic levels of thrombogenic markers, interleukin (IL)-6, and TXA between patients who received intravenous (IV) TXA and those who received topical TXA. Methods: Seventy-six patients scheduled for TKA were enrolled in this randomized double-blinded study. The IV group received 1.0 g of IV TXA before tourniquet inflation and again 3 hours later; a topical placebo was administered 5 minutes before final tourniquet release. The topical group received an IV placebo before tourniquet inflation and again 3 hours later; 3.0 g of TXA was administered topically 5 minutes before final tourniquet release. Peripheral and wound blood samples were collected to measure levels of plasmin-anti-plasmin (PAP, a measure of fibrinolysis), prothrombin fragment 1.2 (PF1.2, a marker of thrombin generation), IL-6, and TXA. Results: At 1 hour after tourniquet release, systemic PAP levels were comparable between the IV group (after a single dose of IV TXA) and the topical group. At 4 hours after tourniquet release, the IV group had lower systemic PAP levels than the topical group (mean and standard deviation, 1,117.8 ± 478.9 µg/L versus 1,280.7 ± 646.5 µg/L; p = 0.049), indicative of higher antifibrinolytic activity after the second dose. There was no difference in PF1.2 levels between groups, indicating that there was no increase in thrombin generation. The IV group had higher TXA levels at all time points (p < 0.001). Four hours after tourniquet release, wound blood IL-6 and TXA levels were higher than systemic levels in both groups (p < 0.001). Therapeutic systemic TXA levels (mean, 7.2 ± 7.4 mg/L) were noted in the topical group. Calculated blood loss and the length of the hospital stay were lower in the IV group (p = 0.026 and p = 0.025). Conclusions: Given that therapeutic levels were reached with topical TXA and the lack of a major difference in the mechanism of action, coagulation, and fibrinolytic profile between topical TXA and a single dose of IV TXA, it may be a simpler protocol for institutions to adopt the use of a single dose of IV TXA when safety is a concern. Level of Evidence: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.
- 1 May 2019
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 101 (9) , 812-820
Addition of Adductor Canal Block to Periarticular Injection for Total Knee Replacement
Background: Periarticular injection is a popular method to control postoperative pain after total knee replacement. An adductor canal block is a sensory block that can also help to alleviate pain after total knee replacement. We hypothesized that the combination of adductor canal block and periarticular injection would allow patients to reach discharge criteria 0.5 day faster than with periarticular injection alone. Methods: This prospective trial enrolled 56 patients to receive a periarticular injection and 55 patients to receive an adductor canal block and periarticular injection. Both groups received intraoperative neuraxial anesthesia and multiple different types of pharmaceutical analgesics. The primary outcome was time to reach discharge criteria. Secondary outcomes, collected on postoperative days 1 and 2, included numeric rating scale pain scores, the PAIN OUT questionnaire, opioid consumption, and opioid-related side effects. Results: There was no difference in time to reach discharge criteria between the groups with and without an adductor canal block. The Wilcoxon-Mann-Whitney odds ratio was 0.87 (95% confidence interval [CI], 0.55 to 1.33; p = 0.518). The median time to achieve discharge criteria (and interquartile range) was 25.8 hours (23.4 hours, 44.3 hours) in the adductor canal block and periarticular injection group compared with 26.4 hours (22.9 hours, 46.2 hours) in the periarticular injection group. Patients who received an adductor canal block and periarticular injection reported lower worst pain (difference in means, −1.4 [99% CI, −2.7 to 0]; adjusted p = 0.041) and more pain relief (difference in means, 12% [99% CI, 0% to 24%]; adjusted p = 0.048) at 24 hours after anesthesia. There was no difference in any other secondary outcome measure (e.g., opioid consumption, opioid-related side effects, numeric rating scale pain scores). Conclusions: The time to meet the discharge criteria was not significantly different between the groups. In the adductor canal block and periarticular injection group, the patients had lower worst pain and greater pain relief at 24 hours after anesthesia. No difference was noted in any other secondary outcome measure (e.g., opioid consumption, opioid-related side effects, numeric rating scale pain scores). Level of Evidence: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.
- 1 May 2019
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 101 (9) , 812-820
Addition of Adductor Canal Block to Periarticular Injection for Total Knee Replacement
Background: Periarticular injection is a popular method to control postoperative pain after total knee replacement. An adductor canal block is a sensory block that can also help to alleviate pain after total knee replacement. We hypothesized that the combination of adductor canal block and periarticular injection would allow patients to reach discharge criteria 0.5 day faster than with periarticular injection alone. Methods: This prospective trial enrolled 56 patients to receive a periarticular injection and 55 patients to receive an adductor canal block and periarticular injection. Both groups received intraoperative neuraxial anesthesia and multiple different types of pharmaceutical analgesics. The primary outcome was time to reach discharge criteria. Secondary outcomes, collected on postoperative days 1 and 2, included numeric rating scale pain scores, the PAIN OUT questionnaire, opioid consumption, and opioid-related side effects. Results: There was no difference in time to reach discharge criteria between the groups with and without an adductor canal block. The Wilcoxon-Mann-Whitney odds ratio was 0.87 (95% confidence interval [CI], 0.55 to 1.33; p = 0.518). The median time to achieve discharge criteria (and interquartile range) was 25.8 hours (23.4 hours, 44.3 hours) in the adductor canal block and periarticular injection group compared with 26.4 hours (22.9 hours, 46.2 hours) in the periarticular injection group. Patients who received an adductor canal block and periarticular injection reported lower worst pain (difference in means, −1.4 [99% CI, −2.7 to 0]; adjusted p = 0.041) and more pain relief (difference in means, 12% [99% CI, 0% to 24%]; adjusted p = 0.048) at 24 hours after anesthesia. There was no difference in any other secondary outcome measure (e.g., opioid consumption, opioid-related side effects, numeric rating scale pain scores). Conclusions: The time to meet the discharge criteria was not significantly different between the groups. In the adductor canal block and periarticular injection group, the patients had lower worst pain and greater pain relief at 24 hours after anesthesia. No difference was noted in any other secondary outcome measure (e.g., opioid consumption, opioid-related side effects, numeric rating scale pain scores). Level of Evidence: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.
- 28 February 2019
- Published by Wiley in Knee Surgery, Sports Traumatology, Arthroscopy
- Vol. 27 (7) , 2140-2144
Posterior condylar bone resection and femoral implant thickness vary by up to 3 mm across implant systems: implications for flexion gap balancing
The purpose of this study was to evaluate the thickness of medial and lateral posterior femoral condylar bone resected with five implant systems using posterior referencing jigs set at 3° of external rotation. The hypothesis was that posterior condylar resection thickness on the medial side would be equal to the thickness of the femoral implant posteriorly, regardless of implant system.
- 28 February 2019
- Published by Wiley in Knee Surgery, Sports Traumatology, Arthroscopy
- Vol. 27 (7) , 2140-2144
Posterior condylar bone resection and femoral implant thickness vary by up to 3 mm across implant systems: implications for flexion gap balancing
The purpose of this study was to evaluate the thickness of medial and lateral posterior femoral condylar bone resected with five implant systems using posterior referencing jigs set at 3° of external rotation. The hypothesis was that posterior condylar resection thickness on the medial side would be equal to the thickness of the femoral implant posteriorly, regardless of implant system.